Severe Sepsis
192
2
5
120
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
20 trials with published results (10%)
Research Maturity
120 completed trials (63% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
12.0%
23 terminated out of 192 trials
83.9%
-2.6% vs benchmark
19%
37 trials in Phase 3/4
17%
20 of 120 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 120 completed trials
Clinical Trials (192)
A Multi-Center Data System and Collaborative Network in China for Severe Infection and Sepsis Children
GM-CSF to Decrease ICU Acquired Infections
L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney Injury
Clinical Study on Monitoring the Plasma Concentration of Ceftazidime-Avibactam in Critically Ill Patients
Alveolar Dead Space as Predictor of Organ Failure in Severe Sepsis
Monocyte Distribution Width (MDW) in the General Population of Emergency Department Patients With and Without Bacteremia
Zinc Therapy in Critical Illness
Endothelium in Severe Sepsis
Early Metabolic Resuscitation for Septic Shock
Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy - Observational Long-term Outcome Follow up
Sepsis Clinical Decision Support [CDS] Master Enrollment Study Protocol
Plasma Inducible Nitric Oxide Synthase (iNOS) Assay and Sepsis Study
The Efficacy of Si-Ni-Tang (a Chinese Herbal Formula) for Severe Sepsis
Symphony IL-6 Study in Patients at Risk of Severe Sepsis
Septic cArdiac Deficiency and MenIngococcal seveRe Sepsis
Symphony IL-6 Cutoff Establishment Study for Patients at Risk of Severe Sepsis Due to COVID-19
Symphony IL-6 Cutoff Validation Study for Patients at Risk of Severe Sepsis
Role of Ulinastatin in Preventing Severe Sepsis and Consequent Morbidities and Mortality
ED Tracking Sheet Implementation
Lotta Alla Sepsi Ospedaliera - Fighting Hospital Sepsis